A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease is characterized by the presence of cortical amyloid-beta (Aβ) protein plaques, which result from the sequential action of β-secretase and γ-secretase on amyloid precursor protein. Semagacestat is a small-molecule γ-secretase inhibitor that was developed as a potential treatment for Alzheimer's disease. METHODS: We conducted a double-blind, placebo-controlled trial in which 1537 patients with probable Alzheimer's disease underwent randomization to receive 100 mg of semagacestat, 140 mg of semagacestat, or placebo daily. Changes in cognition from baseline to week 76 were assessed with the use of the cognitive subscale of the Alzheimer's Disease Assessment Scale for cognition (ADAS-cog), on which scores range from 0 to 70 and higher scores indicate greater cognitive impairment, and changes in functioning were assessed with the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale, on which scores range from 0 to 78 and higher scores indicate better functioning. A mixed-model repeated-measures analysis was used. RESULTS: The trial was terminated before completion on the basis of a recommendation by the data and safety monitoring board. At termination, there were 189 patients in the group receiving placebo, 153 patients in the group receiving 100 mg of semagacestat, and 121 patients in the group receiving 140 mg of semagacestat. The ADAS-cog scores worsened in all three groups (mean change, 6.4 points in the placebo group, 7.5 points in the group receiving 100 mg of the study drug, and 7.8 points in the group receiving 140 mg; P=0.15 and P=0.07, respectively, for the comparison with placebo). The ADCS-ADL scores also worsened in all groups (mean change at week 76, -9.0 points in the placebo group, -10.5 points in the 100-mg group, and -12.6 points in the 140-mg group; P=0.14 and P<0.001, respectively, for the comparison with placebo). Patients treated with semagacestat lost more weight and had more skin cancers and infections, treatment discontinuations due to adverse events, and serious adverse events (P<0.001 for all comparisons with placebo). Laboratory abnormalities included reduced levels of lymphocytes, T cells, immunoglobulins, albumin, total protein, and uric acid and elevated levels of eosinophils, monocytes, and cholesterol; the urine pH was also elevated. CONCLUSIONS: As compared with placebo, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability. Semagacestat was associated with more adverse events, including skin cancers and infections. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT00594568.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, participants experienced adverse reactions such as gastrointestinal symptoms, skin cancer, and infections, which are speculated to be related to the inhibition of other γ-secretase substrates, including notch, CD44, ErbB4, and cadherin.438–441”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [438]
In the citing paper
“Disappointingly, the use of γ-secretase inhibitors (GSIs) has shown limited efficacy in treating Alzheimer's disease [113].”
From The low-density lipoprotein receptor: Emerging post-transcriptional regulatory mechanisms (2025) · cites this paper as [113]
In the citing paper
“Several drugs that have shown promising results in Alzheimer mouse models have failed to prevent cognitive decline in late-phase clinical trials87–89.”
From The use of brain organoids to investigate neural development and disease (2017) · cites this paper as [88]
In the citing paper
“However, with the failures or unsatisfactory efficacy of drugs anti-Aβ [9, 208–211], the development of drugs targeting other targets is increasing, such as anti-tau pathology and anti-neuroinflammation [212].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [208]
In the citing paper
“Semagacestat was the first GSI to enter a phase 3 trial for AD. However, the trial was halted early due to concerns of worsening cognition, increased incidence of skin cancers and infection, and weight loss relative to placebo (Doody et al., 2013).”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Doody et al., 2013
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease
Galasko, D., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00005 · Cited by 1,194
Self-citationO’Bryant, S. E. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1091 · Cited by 884
Wong, G. T., Manfra, D., Poulet, F. M., Zhang, Q., Josien, H., Bara, T., Engstrom, L., Pinzon-Ortiz, M., Fine, J. S., Lee, H.-J. J., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311652200 · Cited by 718
Mohs, R. C., Knopman, D., Petersen, R. C., Ferris, S. H., Ernesto, C., Grundman, M., Sano, M., Bieliauskas, L., Geldmacher, D., Clark, C., et al. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00003 · Cited by 692
Self-citationClinical Gerontology: A Guide to Assessment and Intervention
Brink, T. L. (1986) · Medical Entomology and Zoology · Cited by 594
Geling, A., Steiner, H., Willem, M., Bally‐Cuif, L., & Haass, C. (2002) · The EMBO Reports · doi:10.1093/embo-reports/kvf124 · Cited by 497
The mechanism of γ‐Secretase dysfunction in familial Alzheimer disease
Chávez‐Gutiérrez, L., Bammens, L., Benilova, I., Vandersteen, A., Benurwar, M., Borgers, M., Lismont, S., Zhou, L., Van Cleynenbreugel, S., Esselmann, H., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.79 · Cited by 495
Research works printed but not linked: 2
- Wimo A, Wetterholm A-L, Mastey V, Winbald B. Evaluation of the healthcare resource utilization and caregiver time in anti-dementia drug trials. In: Wimo A, Jönsson B, Karlsson G, Winblad B, eds. The health economics of dementia. London: Wiley, 1998:465-99.
- Kind P. The EuroQol instrument: an index of health-related quality of life. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996:191-201.
Cited by
Items 901–1,000 of 1,002
Efficacy of medications in controlling cognitive dysfunction in Alzheimer’s : a systematic review
de Andrade, S. M., Rodrigues, Í. S. M., Rosa, L. M. V., Taminato, R. L., & dos Santos, G. A. A. (2025) · Dementia & Neuropsychologia · doi:10.1590/1980-5764-dn-2024-0243 · Cited by 6
The manipulator behind “Scissors”: γ -secretase and its modulators in Alzheimer’s disease
Ning, G., Fan, X., Du, J., wenxue, Z., Sijia, W., Meinei, C., Xiaolong, D., & Yiming, Q. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1637671 · Cited by 5
Repurposing nirogacestat, a gamma secretase enzyme inhibitor in desmoid tumors
Tansir, G., Rastogi, S., & Gounder, M. M. (2025) · Future Oncology · doi:10.1080/14796694.2025.2550826 · Cited by 6
“Agents such as avagacestat and semagacestat were examined in phase 2 and 3 trials, respectively, with the findings precluding their further clinical use [24,25].”
A Question of Origins: Non-neuronal Sources of Amyloid-β
Sasmita, A. O., & Depp, C. (2026) · Neuroscience Bulletin · doi:10.1007/s12264-025-01572-4 · Cited by 5
“…functions of BACE and γ-secretase are further highlighted by the failure of various AD clinical trials exploring the feasibility of β-and γ-secretase inhibitors [37, 38], primarily due to adverse effects, which included hippocampal shrinkage in the case of the BACE inhibitor, verubecestat [39].”
Nonhuman Primate Models of Human Disease
Cann, J. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417144-2.00013-5 · Cited by 5
Homma, G., & Yoshida, T. (2023) · Pharmaceutical Statistics · doi:10.1002/pst.2337 · Cited by 5
Novel therapeutic approaches for targeting Alzheimer’s disease
Khodakiya, A., Chaudhary, S., Chaudhary, A., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00020-0 · Cited by 5
Substrate Selection Criteria in Regulated Intramembrane Proteolysis
Moser, C., Guschtschin-Schmidt, N., Silber, M., Flum, J., & Muhle‐Goll, C. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00068 · Cited by 5
Costa, A. C. S. (2024) · Brain Sciences · doi:10.3390/brainsci14111084 · Cited by 5
“Therefore, it is not surprising that lowering A β using secretase inhibitors has been associated with accelerated cognitive decline and brain atrophy of whole brain and hippocampus in some clinical trials [105–107].”
Gao, Y., Schedin‐Weiss, S., & Tjernberg, L. O. (2024) · Advanced technology in neuroscience . · doi:10.4103/atn.atn-d-24-00014 · Cited by 9
Kahle‐Wrobleski, K., Fillit, H. M., Kurlander, J., Reed, C. C., & Belger, M. A. (2014) · The European Journal of Health Economics · doi:10.1007/s10198-014-0648-7 · Cited by 8
“The protocols were subsequently amended prior to completion in order to allow for continued safety monitoring of patients [21].”
MethodInfluentialDual Function of Notch Signaling in Cancer: Oncogene and Tumor Suppressor
Koch, U., & Radtke, F. (2018) · Springer eBooks · doi:10.1007/978-1-4939-8859-4_3 · Cited by 5
Puerto, A. M. H., Russo, C., & Fregni, F. (2018) · Neuromethods · doi:10.1007/978-1-4939-7880-9_9 · Cited by 10
Flavonoids as emerging notch signaling pathway modulators in cancer
Singh, A. K., & Kumar, S. (2023) · Journal of Asian Natural Products Research · doi:10.1080/10286020.2023.2202854 · Cited by 5
Alzheimer’s Disease: Treatment Today and Tomorrow
Gorthi, S. P., & Gupta, D. (2023) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_254_23 · Cited by 5
Prospects and Challenges for Alzheimer Therapeutics
Wolfe, M. S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00023-x · Cited by 5
Alzheimer’s Disease Cerebrospinal Fluid (CSF) Biomarkers
Khan, T. K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-804832-0.00005-5 · Cited by 5
Chau, S. A., Liu, C. S., Ruthirakuhan, M. T., Lanctôt, K. L., & Herrmann, N. (2016) · Mental health and illness worldwide · doi:10.1007/978-981-10-0370-7_20-1 · Cited by 5
Current clinical approaches in neurodegenerative diseases
Gago, M. F., Machado, Á. S., & Rocha, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818084-6.00004-0 · Cited by 5
Oral Amylin Treatment Reduces the Pathological Cascade of Alzheimer’s Disease in a Mouse Model
Na, H., Tian, H., Zhang, Z., Li, Q., Yang, J. B., Mcparland, L., Gan, Q., & Qiu, W. Q. (2021) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/15333175211012867 · Cited by 6
The Ups and Downs of Amyloid in Alzheimer's
Siemers, E., Aisen, P. S. S., & Carrillo, M. C. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2021.54 · Cited by 5
“J Prev Alz Dis 2022;1(9):92-95, http://dx.”
BackgroundSelf-citationRecent advances in small molecule stimulation of regeneration and repair
Silpa, L., Sim, R. R. Y., & Russell, A. J. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128601 · Cited by 5
Neuroprotection in Alzheimer Disease
Jain, K. (2019) · Springer Protocols Handbooks · doi:10.1007/978-1-4939-9465-6_8 · Cited by 4
Has molecular imaging delivered to drug development?
Murphy, P. S., Patel, N., & McCarthy, T. J. (2017) · Philosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rsta.2017.0112 · Cited by 5
“to measuring the extent of amyloid clearance [12,13].”
BackgroundLan, M. J., Ogden, R. T., Kumar, D. J. S., Stern, Y., Parsey, R. V., Pelton, G. H., Rubin‐Falcone, H., Pradhaban, G., Zanderigo, F., Miller, J. M., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161284 · Cited by 5
Alzheimer's disease: the large gene instability hypothesisPreprint
Soheili‐Nezhad, S. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/189712 · Cited by 5
γ-Secretase fanning the fire of innate immunity
Liu, C., Nikain, C., & Li, Y.-M. (2023) · Biochemical Society Transactions · doi:10.1042/bst20221445 · Cited by 4
MicroRNA and Alzheimer’s disease: Diagnostic biomarkers and potential therapeutic targets
Huang, Y., Chen, Y., He, Z., Lu, W., Lai, H., Wang, Y., & Wang, J. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00002 · Cited by 8
Boosting Neurogenesis as a Strategy in Treating Alzheimer’s Disease
Dwamena, A. A., Arachchi, R. Y. B., & Wang, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188926 · Cited by 5
“For instance, drugs like Semagacestat and Bapineuzumab successfully reduced A β and tau levels, but failed to improve cognition, and in some cases, worsened it [14,15].”
Callaghan, J. F., & Mattingly, R. R. (2025) · Cancers · doi:10.3390/cancers17233781 · Cited by 4
“These agents were repurposed from Alzheimer’s disease to treat cancer due to their ability to inhibit the cleavage of Notch family proteins and blocking the Notch signaling pathway [71–73].”
Alzheimer’s Disease: Evolving Therapeutics, Scientific Progress, and Key Challenges
Sai Yasasvi, K., Goswami, A. K., Prasad, M. R., Chauhan, V. S., & Yadav, N. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02468 · Cited by 6
Park, I., Lee, D., Hong, R. S., Kim, H. R., & Kim, Y. (2026) · Experimental Neurobiology · doi:10.5607/en25040 · Cited by 4
“Due to cognitive worsening and dose-limiting Notch-related toxicity, the phase 3 trials were terminated early [50].”
The Role of T Cells in Alzheimer's Disease Pathogenesis
Zhao, J., Wang, X., He, Y., Xu, P., Lai, L., Chung, Y., & Pan, X. (2023) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2023050145 · Cited by 4
Shah, F. A., Qadir, H., Khan, J., & Faheem, M. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.03.064 · Cited by 4
Bušek, P., Převorovský, M., Krepela, E., & Šedo, A. (2014) · Springer eBooks · doi:10.1007/978-3-7091-1431-5_12 · Cited by 4
Exploration of the Medicinal Peptide Space
Gevaert, B., Stalmans, S., Wynendaele, E., Taevernier, L., Bracke, N., D’Hondt, M., & Spiegeleer, B. M. J. D. (2016) · Protein and Peptide Letters · doi:10.2174/0929866523666160215162326 · Cited by 4
Puangmalai, N., Somani, A., Thangnipon, W., Ballard, C. G., & Broadstock, M. (2015) · EXCLI journal · doi:10.17179/excli2015-560 · Cited by 4
Kaur, G., & Goyal, B. (2022) · ChemistrySelect · doi:10.1002/slct.202202561 · Cited by 4
Drug Discovery from Medicinal Plants against Alzheimer's Disease
Marzouk, M. M., Farid, M. M., Hegazi, N. M., & Ezzat, S. M. (2023) · Wiley eBooks · doi:10.1002/9781119794127.ch3 · Cited by 4
Cognitive Enhancers and Treatments for Alzheimer’s Disease
Devanand, D. P., & Fremont, R. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_139 · Cited by 4
GNG5 is a novel regulator of Aβ42 production in Alzheimer’s disease
Li, C., Yang, Y., Luo, S., Qiu, W., Wang, X., & Ge, W. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-07218-z · Cited by 4
“However, Eli Lilly ’ s small-molecule γ -secretase inhibitor, semagacestat, faced failure in Phase 3 clinical trials because of adverse events such as skin cancer and infections [4].”
Ding, G., Li, Y., Li, D., Dou, M., Fu, C., Chen, T., Cui, X., Zhang, Q., Yang, P., Hou, Y., et al. (2024) · Journal of Virology · doi:10.1128/jvi.01216-24 · Cited by 4
Xu, X., Ghosh, D., Luo, S., & Database, F. T. C. I. P. (2025) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2025.2458018 · Cited by 6
“…co-primary endpoint strategy, requiring significance across all endpoints for treatment efficacy assertion, adopted in studies such as Semagace-stat (Doody et al., 2013), EXPEDITION (Doody et al., 2014), LMTM (Gauthier et al., 2016), and ADMET 2 (Mintzer et al., 2021), or multiple endpoint…”
MethodFerrero-Arias, J., & Turrión-Rojo, M. Á. (2015) · Neurología · doi:10.1016/j.nrl.2015.03.015 · Cited by 4
DeFeis, B. L., Ying, G., Kurasz, A. M., Wit, L. D., Amofa, P., Chandler, M. J., Locke, D. E. C., Shandera‐Ochsner, A. L., Phatak, V. S., & Smith, G. E. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210582 · Cited by 4
Down syndrome: a model for chromosome abnormalities
Overk, C., & Mobley, W. C. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00007-1 · Cited by 4
Quantitative comparison of presenilin protein expression reveals greater activity of PS2‐γ‐secretase
Eccles, M. K., Main, N., Carlessi, R., Armstrong, A. M., Sabale, M., Roberts‐Mok, B., Tirnitz‐Parker, J. E. E., Agostino, M., Groth, D. M., Fraser, P. E., et al. (2023) · The FASEB Journal · doi:10.1096/fj.202300954rr · Cited by 4
UPDATE ON PREVENTION TRIALS IN ALZHEIMER’S DISEASE
Vellas, B. J. (2014) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2014.30 · Cited by 5
“, (5-7)), as well as accumulating research demonstrating that AD pathologic process begins decades before the appearance of symptoms (e.”
BackgroundSelf-citationγ-Secretase Inhibitors: From Chemical Probes to Drug Development
Hur, J., Gertsik, N., Johnson, D. S., & Li, Y.-M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802173-6.00004-6 · Cited by 4
Liao, F., & Holtzman, D. M. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2802 · Cited by 4
Thiamine pyrophosphokinase deficiency induces Alzheimer’s pathologyPreprint
Sang, S., Qian, T., Cai, F., Qiu, H., Xu, Y., Zhang, Y., Zhang, Q., Huang, S., Jiang, D., Wu, Y., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.09.141358 · Cited by 4
Delre, P., Caporuscio, F., Saviano, M., & Mangiatordi, G. F. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12793685 · Cited by 4
Lah, J. J., Tandon, R., Zhao, L., Watson, C. M., Elmor, M. B., Heilman, C. J., Sanders, K., Hales, C. M., Yang, H., Loring, D. W., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2577025/v1 · Cited by 9
Covalent fragment inhibits intramembrane proteolysis
Eden, A., Zhao, J., Xiao, Y., Gibson, J., & Wang, C. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.958399 · Cited by 3
“I-CLiPs are critical for a myriad of biological processes and therefore are implicated in a number of disease pathologies like AD (Winter-Vann and Casey, 2005; Lichtenthaler et al., 2011; Düsterhöft et al., 2017).”
BackgroundCognitive Enhancers and Treatments for Alzheimer’s Disease
Devanand, D. P., & Fremont, R. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_139-1 · Cited by 4
Mishra, A. K., Srivastava, A., Raj, V., Saini, V., Khan, G., Singh, H., Mishra, A., & Paliwal, S. (2024) · Current Alzheimer Research · doi:10.2174/0115672050361294241211071813 · Cited by 4
γ-secretase targeting in Alzheimer's disease
Du, L., Li, G., Wei, Y., & Han, G. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251349529 · Cited by 4
“79,80 Avagacestat (BMS-708163) exhibited greater selectivity for APP-C99 over Notch 1 than semagacestat did.”
Sajimon, M., Wheeler, C. J., Foley, A. R., Chan, K., Griffin, M. N., Dinakarapandian, D. M., Holberton, A. L., Joy, J., Paravastu, A. K., Wood, L. B., et al. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00544 · Cited by 3
Modulation of an aberrant basal cell program in human alveolar epithelial spheroids and lung slices
Li, Y., Wellmerling, J. H., Rosas, L., Link, P. A., Chow, D., Alvarez, J., Choi, K. M., Espinosa, A. M. D., Gilbert, R. M., Goplen, N., et al. (2025) · Respiratory Research · doi:10.1186/s12931-025-03441-0 · Cited by 4
“In addition, pan-Notch inhibitors have serious Notch-associated adverse events [77].”
Amyloid-β clearance: an astrocytic perspective
Li, J., Lv, Z., Chen, X. P., Fu, F., Yang, K., Lai, G., Wu, H., & Xie, G. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1812081 · Cited by 3
“However, clinical trials of β - and γ -secretase inhibitors such as semagacestat and verubecestat showed limited efficacy and were further constrained by adverse effects and tolerability concerns (Doody et al., 2013; Egan et al., 2019).”
Nassir, C. M. N. C. M., Vishnumukkala, T., Gopalakrishna, P. K., Jagadeesan, S., Nor, N. H. M., Mehat, M. Z., Moklas, M. A. M., Hein, Z. M., & Kamaruzzaman, M. A. (2026) · Biomedicines · doi:10.3390/biomedicines14071609 · Cited by 3
“…and 5xFAD transgenic mice, paradoxically impaired cognitive function in a Phase III trial, likely due to the non-selective inhibition of Notch signaling, a consequence not anticipated by amyloid-centric mouse models that fail to replicate the complete spectrum of γ -secretase substrates [115].”
Wu, G., Wu, Z., Sang, N., & Hershey, J. C. (2015) · International Journal of Neuroscience · doi:10.3109/00207454.2014.952730 · Cited by 3
“Two recent clinical trials with γ -secretase inhibitors have failed to show cognitive improvement in patients with AD [33,34].”
BackgroundThe Amyloid Cascade Hypothesis
Lewis, T. J., & Trempe, C. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-812112-2.00002-1 · Cited by 3
Hegberg, N. J., Dev, S. I., & Hayes, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108552684.040 · Cited by 3
Reconsidering and Reforming the Amyloid Cascade Hypothesis
Uddin, M. S., Kabir, M. T., Behl, T., & Ashraf, G. M. (2021) · Current Protein and Peptide Science · doi:10.2174/1389203722666210322151627 · Cited by 3
Presenilin-1 in smooth muscle cells facilitates hypermuscularization in elastin aortopathy
Saito, J., Dave, J. M., Lau, F. D., & Greif, D. M. (2023) · iScience · doi:10.1016/j.isci.2023.108636 · Cited by 3
Understanding the Modulatory Role of E2012 on the γ-Secretase–Substrate Interaction
Guzmán‐Ocampo, D. C., Aguayo‐Ortiz, R., & Domínguez, L. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c01993 · Cited by 4
Niazi, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810211 · Cited by 3
“Semagacestat [140] Gamma-secretase inhibitor aimed at reducing amyloid-beta production.”
BackgroundChauhan, B. S., Singh, Y. P., Pöeggeler, B., & Singh, S. K. (2025) · Current Alzheimer Research · doi:10.2174/0115672050366727250513061730 · Cited by 3
Hayama, T., Murakami, K., Watanabe, T., Maeda, R., Kamata, M., & Kondo, S. (2015) · Brain Research · doi:10.1016/j.brainres.2015.12.020 · Cited by 3
Chemical Modulators of Protein Misfolding, Neurodegeneration and Tau
Seneci, P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801944-3.00001-1 · Cited by 3
Substrate-Selective Enzyme Inhibitors
Chu, Q., Chang, T., & Saghatelian, A. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.07.009 · Cited by 3
Bayraktar, A., Önal-Süzek, T., Süzek, B. E., & Baysal, Ö. (2019) · arXiv (Cornell University) · doi:10.48550/arxiv.1909.07469 · Cited by 3
“Proposed treatments, e.g. vaccines (Schneeberger et al., 2009), are mostly palliative (Fargo & Bleiler, 2014; Jankovic, 2008); many could not be able to pass beyond phase 3 level trials (Doody et al., 2013; Karran & Hardy, 2014).”
BackgroundGeriatric models of care for neurodegenerative disorders
van der Marck, M. A., Fultz, B. A., & Callahan, C. M. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804766-8.00004-2 · Cited by 3
Kikuchi, M., Adachi, N., Matsumaru, N., & Tsukamoto, K. (2019) · Pharmaceutical Medicine · doi:10.1007/s40290-019-00306-y · Cited by 3
Discovery of small molecules for the treatment of Alzheimer’s disease
Rao, P. P. N., Pham, A. T., & Shakeri, A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818349-6.00011-x · Cited by 4
Mosser, S., Gerber, H., & Fraering, P. C. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15143 · Cited by 3
“…worsening, alterations of immune cells, gastrointestinal symptoms, and skin cancers, were mainly attributed to impaired processing of Notch and APP (Doody et al., 2013), likely causing simultaneously altered Notch signaling pathway and accumulation in the brain of APP-CTFα/β. Collectively, it…”
BackgroundResultIzuo, N., Shimizu, T., Murakami, K., & Irie, K. (2021) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.20-00251-5 · Cited by 3
Narlawar, R., Serneels, L., Gaffric, C., Gijsen, H. J. M., Strooper, B. D., & Bischoff, F. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115725 · Cited by 3
Reduction of Amyloid-β Production without Inhibiting Secretase Activity by MS-275
Mitsuishi, Y., Nakano, M., Kojima, H., Okabe, T., & Nishimura, M. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00848 · Cited by 3
Human Diseases Associated with Notch Signalling: Lessons from Drosophila melanogaster
Megaly, M., Turgambayeva, A., Hallam, R. D., Foran, G., Megaly, M., & Necakov, A. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2906234 · Cited by 5
Aguilera, M., Mathis, C., Herbeaux, K., Isik, A., Faranda, D., Battaglia, D. A., & Goutagny, R. (2025) · Imaging Neuroscience · doi:10.1162/imag.a.70 · Cited by 3
Ousset, P., Delrieu, J., & Vellas, B. J. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt228 · Cited by 3
Self-citationSubstrate-based chemical probes for Alzheimer’s γ-secretase
Wolfe, M. S. (2020) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02565-w · Cited by 4
Tau and beta-amyloid in Alzheimer’s Disease: Theories, treatments strategies, and future directions
Colautti, J., & Nagales, K. (2020) · The Meducator · doi:10.15173/m.v1i37.2502 · Cited by 3
Alzheimer’s Disease: Causes, Mechanisms, and Steps Toward Prevention
Choi, S. H., & Tanzi, R. E. (2020) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780190069162.013.18 · Cited by 3
Alzheimer's Disease and Mild Cognitive Impairment
Jones, D. T., Bruns, M. B., & Petersen, R. C. (2018) · Wiley eBooks · doi:10.1002/9781118772034.ch21 · Cited by 3
Membrane dynamics of Notch-bound γ-secretase produces two distinct Notch conformationsPreprint
Tang, N., Dehury, B., & Kepp, K. P. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/607846 · Cited by 3
Krolak‐Salmon, P. (2020) · NPG. Neurologie, psychiatrie, gériatrie/NPG · doi:10.1016/s1627-4830(20)30195-1 · Cited by 6
Editorial: Beta-Amyloid oligomer specific treatments for Alzheimer's disease
Hillen, H. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1034158 · Cited by 3
“Consequently, a series of gamma secretase (Coric et al., 2012; Doody et al., 2013) and beta secretase (BACE) inhibitors (Panza et al.”
BackgroundWang, D., Ling, Y., Harris, K., Schulz, P. E., Jiang, X., & Kim, Y. (2023) · medRxiv · doi:10.1101/2023.10.27.23297685 · Cited by 4
“9,19 However, our analysis reveals specific subpopulations of mild to moderate AD patients, identified by distinct A levels and hippocampal volume, who might have responded positively to the treatment.”
BackgroundLudwig, M., Birkeland, A. C., Smith, J. D., Gensterblum‐Miller, E., Zhai, J., Kulkarni, A., Jiang, H., & Brenner, J. C. (2024) · Research Square · doi:10.21203/rs.3.rs-3922565/v1 · Cited by 3
Deng, J., Liu, P., Lv, B., Guo, J., Liang, F., Tang, J., & Xie, H. (2015) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2015.03.042 · Cited by 2
Khanna, M. R., & Fortini, M. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-141491 · Cited by 2
Regulated intramembrane proteolysis, innate immunity and therapeutic targets in Alzheimer’s disease
Hurst, T. P., Coleman-Vaughan, C., Patwal, I., & McCarthy, J. V. (2016) · AIMS molecular science · doi:10.3934/molsci.2016.2.138 · Cited by 2
“The type I interferons (IFNs) bind surface receptors (IFNARs) and induce a signalling cascade via the Janus kinase (JAK)-signal-transducer and activator of transcription [59] pathway to induce IFN-stimulated gene (ISG) expression, reviewed in [60].”
Wu, X., Zhu, L., Wang, G., Zhang, Q., & Qian, Z. (2023) · Physical Chemistry Chemical Physics · doi:10.1039/d3cp03883a · Cited by 2
Strope, T. A., Troutwine, B., Hauger, B. M., Smith, K. P., Swerdlow, R. H., & Wilkins, H. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251360243 · Cited by 3
“28 – 30 These early therapeutics failed, and some worsened AD progression.”
Role of BACE1 in Cognitive Function, from Alzheimer’s Disease to Traumatic Brain Injury
Lombardo, S., & Tesco, G. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802851-3.00008-5 · Cited by 1
Liu, S., Zhao, Y., Su, X., Zhou, C., Yang, P., Lin, Q., Li, S., Tan, H., Wang, Q., Wang, C., et al. (2020) · Stem Cells International · doi:10.1155/2020/8897494 · Cited by 2
A Global Review on Alzheimer’s Disease
Natarajan., P., Mumthaj., P., Vijay., J., & Gokul., V. (2021) · International Journal of Pharmaceutical Sciences Review and Research · doi:10.47583/ijpsrr.2021.v68i01.017 · Cited by 4
Metadata
- Authors
- Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., Aisen, P. S., Siemers, E., Sethuraman, G., & Mohs, R.
- Affiliations
- Baylor College of Medicine (US)
- University of California San Diego (US)
- Indiana University (US)
- The University of Tokyo (JP)
- Hôpital de La Grave (FR)
- Boston Children's Hospital (US)
- University of Rochester Medicine (US)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-25
- Volume
- 369
- Issue
- 4
- Pages
- 341-350
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2118935254
- Cited by
- 1,224
- References
- 24
- Citations by year
- 2026: 41 · 2025: 69 · 2024: 85 · 2023: 84 · 2022: 93 · 2021: 91 · 2020: 140 · 2019: 118 · 2018: 109 · 2017: 99 · 2016: 106 · 2015: 88 · 2014: 77 · 2013: 22
- FWCI
- 68.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (U19AG010483)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- semagacestat, Alzheimer's disease, gamma-secretase inhibitors, amyloid plaques, cognitive decline, activities of daily living, adverse events, skin cancer, lymphopenia, immunosuppression, drug safety, trial termination, dose comparison, ADAS-Cog, amyloid precursor protein, beta-secretase, gamma-secretase, treatment discontinuation
- MeSH terms
- Activities of Daily Living, Aged, Alanine, Alzheimer Disease, Azepines, Cognition, Double-Blind Method, Female, Humans, Male, Middle Aged, Skin Neoplasms, Biomarkers, Weight Loss, Amyloid beta-Peptides, Treatment Failure, Amyloid Precursor Protein Secretases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.